- Email: [email protected]
Gastroenteropancreatic Neuroendocrine Tumors (Gepnet) Registry: Update from an International Collaboration
Annals of Oncology 25 (Supplement 4): iv394–iv405, 2014 doi:10.1093/annonc/mdu345.10
neuroendocrine & endocrine tumours and cup
abstracts
GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS (GEPNET) REGISTRY: UPDATE FROM AN INTERNATIONAL COLLABORATION
S. Yalcin1, S. Glasberg2, H. Abali3, F. Aykan4, L. Bai5, J. Kattan6, H.Y. Lim7, Y. S. Park8, H. Raef9, J. Ramos10, K. Rau11, S. Saglam4, S. Serdengecti12, A. Sevinc13, Y. Shan14, Y. Shyr15, V. Sriuranpong16, S.N. Turhal17, K. Yeh18, T. Hwang19 1 Medical Oncology, Hacettepe University Faculty of Medicine, Ankara, TURKEY 2 Neuroendcrine Tumor Unit, Endocrinology and Metabolism Service, The Hadassah-Hebrew University Medical Center, Jerusalem, ISRAEL 3 Medical Oncology, Baskent University Faculty of Medicine Adana Uygulama Ve Arastirma Mer., Adana, TURKEY 4 Medical Oncology, Istanbul University Institute of Oncology, Istanbul, TURKEY 5 Medical Oncology, Chian Medical University Hospital, Taichung, TAIWAN 6 Dept. of Hematology/oncology, Hotel Dieu de France Hospital, Beirut, LEBANON 7 Dept. Medical Oncology, National Cancer Center, SINGAPORE 8 Medicine, Samsung Medical Center, Seoul, KOREA 9 Department of Medicine, King Faisal Specialist Hospital and Research Centre, Riyadh, SAUDI ARABIA 10 HPB Surgery, Wits University Donald Gordon Medical Centre, Johannesburg, SOUTH AFRICA 11 Hematology-oncology, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, TAIWAN 12 Division of Medical Oncology, Department of Internal Medicine, Cerrahpasa Medical Faculty, Istanbul University, Istanbul, TURKEY 13 Medical Oncology Department, Gaziantep University Onkoloji Hastanesi, Gaziantep, TURKEY 14 Department of Surgery, National Cheng Kung University Hospital, Tainan, TAIWAN 15 Department of Surgery, Taipei Veterans General Hospital, Taipei, TAIWAN 16 Division of Medical Oncology, Chulalongkorn University, Bangkok, THAILAND 17 Medical Oncology, Marmara University Hospital, Istanbul, TURKEY 18 Oncology Department, National Taiwan University Hospital, Taipei, TAIWAN 19 Division of General Surgery, Chang-Gang Memorial Hospital-Lin-Kou, Taoyuan, TAIWAN
Aim: Epidemiologic data for GEPNET is lacking in many geographic areas. The aim of the GEPNET Registry is to study the prevalence, incidence, regional trends in diagnosis, and clinical management of GEPNET in the Asia-Pacific, Middle East, Turkey and South Africa. Methods: Patients ( pts) with histopathological diagnosis of GEPNET within 5 years (yrs) of registry entry were included. Pro- and retrospective data were collected at 82 sites. Enrollment in the registry was from July 2009 to December 2012. Follow-up will be for 5 yrs.
© European Society for Medical Oncology 2014. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: [email protected].
Downloaded from https://academic.oup.com/annonc/article-abstract/25/suppl_4/iv398/2241843 by guest on 08 September 2018
1141PD
Results: As of December 1, 2013 (cut-off for this interim analysis), 1005 pts were enrolled, 933 were evaluable. At diagnosis, median age was 54 yrs [range: 12-87], gender ratio was balanced (49% male). The majority of pts (740/933, 77%) had symptoms at the time of diagnosis. Abdominal pain and weight loss were the most commonly reported symptoms. The most frequently reported primary site was the pancreas (42%) followed by the stomach (17%). The majority of pts had well-differentiated tumors (70%). Immunostaining results for Synaptophysin and Chromogranin A were reported for the majority of patients (77% and 82% respectively). Proliferative indices were less frequently reported; mitotic index: 17% and Ki-67: 50% pts. Use of computed tomography scanning was the main modality of disease evaluation (44% pts). Other imaging modalities including functional PET and octreotide scintigraphy were used in <10% pts at diagnosis. The use of serum CgA testing at diagnosis and 24 h urine 5HIAA tests were rarely used (11% and 7% pts), although there was substantial variation by geographic region. The most common initial therapy was surgery (60%) followed by somatostatin analogues (17%) and chemotherapy (16%). Median progression free survival was 57.3 months (95%CI: 52.264.4), and varied by primary tumor site as well as WHO (2004) classification at diagnosis. Conclusions: The GEPNET Registry continues to provide important information as it relates to the diagnosis and treatment of patients in the participating countries. This analysis has highlighted the need for clinical practice improvement to ensure better evaluation of patients. Disclosure: S. Yalcin: Member of Novartis Advisory Board; Institution participates in Novartis-sponsored clinical trials. S. Glasberg: Member of Novartis Advisory Board; Institution participates in Novartis-sponsored clinical trials; H. Abali: Member of Novartis Advisory Board; Institution participates in Novartis-sponsored clinical trials; F. Aykan: Member of Novartis Advisory Board; Institution participates in Novartis-sponsored clinical trials; L. Bai: Member of Novartis Advisory Board; Institution participates in Novartis-sponsored clinical trials; J. Kattan: Member of Novartis Advisory Board; Institution participates in Novartis-sponsored clinical trials; H.Y. Lim: Member of Novartis Advisory Board; Institution participates in Novartis-sponsored clinical trials; Y.S. Park: Member of Novartis Advisory Board; Institution participates in Novartis-sponsored clinical trials; H. Raef: Member of Novartis Advisory Board; Institution participates in Novartis-sponsored clinical trials; J. Ramos: Member of Novartis Advisory Board; Institution participates in Novartis-sponsored clinical trials; K. Rau: Member of Novartis Advisory Board; Institution participates in Novartis-sponsored clinical trials; S. Saglam: Member of Novartis Advisory Board; Institution participates in Novartis-sponsored clinical trials; S. Serdengecti: Member of Novartis Advisory Board; Institution participates in Novartis-sponsored clinical trials; A. Sevinc: Member of Novartis Advisory Board; Institution participates in Novartis-sponsored clinical trials; Y. Shan: Member of Novartis Advisory Board; Institution participates in Novartis-sponsored clinical trials; Y. Shyr: Member of Novartis Advisory Board; Institution participates in Novartis-sponsored clinical trials.; V. Sriuranpong: Member of Novartis Advisory Board; Institution participates in Novartis-sponsored clinical trials; S.N. Turhal: Member of Novartis Advisory Board; Institution participates in Novartis-sponsored clinical trials; K. Yeh: Member of Novartis Advisory Board; Institution participates in Novartis-sponsored clinical trials; T. Hwang: Member of Novartis Advisory Board; Institution participates in Novartis-sponsored clinical trials.
neuroendocrine & endocrine tumours and cup
abstracts
GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS (GEPNET) REGISTRY: UPDATE FROM AN INTERNATIONAL COLLABORATION
S. Yalcin1, S. Glasberg2, H. Abali3, F. Aykan4, L. Bai5, J. Kattan6, H.Y. Lim7, Y. S. Park8, H. Raef9, J. Ramos10, K. Rau11, S. Saglam4, S. Serdengecti12, A. Sevinc13, Y. Shan14, Y. Shyr15, V. Sriuranpong16, S.N. Turhal17, K. Yeh18, T. Hwang19 1 Medical Oncology, Hacettepe University Faculty of Medicine, Ankara, TURKEY 2 Neuroendcrine Tumor Unit, Endocrinology and Metabolism Service, The Hadassah-Hebrew University Medical Center, Jerusalem, ISRAEL 3 Medical Oncology, Baskent University Faculty of Medicine Adana Uygulama Ve Arastirma Mer., Adana, TURKEY 4 Medical Oncology, Istanbul University Institute of Oncology, Istanbul, TURKEY 5 Medical Oncology, Chian Medical University Hospital, Taichung, TAIWAN 6 Dept. of Hematology/oncology, Hotel Dieu de France Hospital, Beirut, LEBANON 7 Dept. Medical Oncology, National Cancer Center, SINGAPORE 8 Medicine, Samsung Medical Center, Seoul, KOREA 9 Department of Medicine, King Faisal Specialist Hospital and Research Centre, Riyadh, SAUDI ARABIA 10 HPB Surgery, Wits University Donald Gordon Medical Centre, Johannesburg, SOUTH AFRICA 11 Hematology-oncology, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, TAIWAN 12 Division of Medical Oncology, Department of Internal Medicine, Cerrahpasa Medical Faculty, Istanbul University, Istanbul, TURKEY 13 Medical Oncology Department, Gaziantep University Onkoloji Hastanesi, Gaziantep, TURKEY 14 Department of Surgery, National Cheng Kung University Hospital, Tainan, TAIWAN 15 Department of Surgery, Taipei Veterans General Hospital, Taipei, TAIWAN 16 Division of Medical Oncology, Chulalongkorn University, Bangkok, THAILAND 17 Medical Oncology, Marmara University Hospital, Istanbul, TURKEY 18 Oncology Department, National Taiwan University Hospital, Taipei, TAIWAN 19 Division of General Surgery, Chang-Gang Memorial Hospital-Lin-Kou, Taoyuan, TAIWAN
Aim: Epidemiologic data for GEPNET is lacking in many geographic areas. The aim of the GEPNET Registry is to study the prevalence, incidence, regional trends in diagnosis, and clinical management of GEPNET in the Asia-Pacific, Middle East, Turkey and South Africa. Methods: Patients ( pts) with histopathological diagnosis of GEPNET within 5 years (yrs) of registry entry were included. Pro- and retrospective data were collected at 82 sites. Enrollment in the registry was from July 2009 to December 2012. Follow-up will be for 5 yrs.
© European Society for Medical Oncology 2014. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: [email protected].
Downloaded from https://academic.oup.com/annonc/article-abstract/25/suppl_4/iv398/2241843 by guest on 08 September 2018
1141PD
Results: As of December 1, 2013 (cut-off for this interim analysis), 1005 pts were enrolled, 933 were evaluable. At diagnosis, median age was 54 yrs [range: 12-87], gender ratio was balanced (49% male). The majority of pts (740/933, 77%) had symptoms at the time of diagnosis. Abdominal pain and weight loss were the most commonly reported symptoms. The most frequently reported primary site was the pancreas (42%) followed by the stomach (17%). The majority of pts had well-differentiated tumors (70%). Immunostaining results for Synaptophysin and Chromogranin A were reported for the majority of patients (77% and 82% respectively). Proliferative indices were less frequently reported; mitotic index: 17% and Ki-67: 50% pts. Use of computed tomography scanning was the main modality of disease evaluation (44% pts). Other imaging modalities including functional PET and octreotide scintigraphy were used in <10% pts at diagnosis. The use of serum CgA testing at diagnosis and 24 h urine 5HIAA tests were rarely used (11% and 7% pts), although there was substantial variation by geographic region. The most common initial therapy was surgery (60%) followed by somatostatin analogues (17%) and chemotherapy (16%). Median progression free survival was 57.3 months (95%CI: 52.264.4), and varied by primary tumor site as well as WHO (2004) classification at diagnosis. Conclusions: The GEPNET Registry continues to provide important information as it relates to the diagnosis and treatment of patients in the participating countries. This analysis has highlighted the need for clinical practice improvement to ensure better evaluation of patients. Disclosure: S. Yalcin: Member of Novartis Advisory Board; Institution participates in Novartis-sponsored clinical trials. S. Glasberg: Member of Novartis Advisory Board; Institution participates in Novartis-sponsored clinical trials; H. Abali: Member of Novartis Advisory Board; Institution participates in Novartis-sponsored clinical trials; F. Aykan: Member of Novartis Advisory Board; Institution participates in Novartis-sponsored clinical trials; L. Bai: Member of Novartis Advisory Board; Institution participates in Novartis-sponsored clinical trials; J. Kattan: Member of Novartis Advisory Board; Institution participates in Novartis-sponsored clinical trials; H.Y. Lim: Member of Novartis Advisory Board; Institution participates in Novartis-sponsored clinical trials; Y.S. Park: Member of Novartis Advisory Board; Institution participates in Novartis-sponsored clinical trials; H. Raef: Member of Novartis Advisory Board; Institution participates in Novartis-sponsored clinical trials; J. Ramos: Member of Novartis Advisory Board; Institution participates in Novartis-sponsored clinical trials; K. Rau: Member of Novartis Advisory Board; Institution participates in Novartis-sponsored clinical trials; S. Saglam: Member of Novartis Advisory Board; Institution participates in Novartis-sponsored clinical trials; S. Serdengecti: Member of Novartis Advisory Board; Institution participates in Novartis-sponsored clinical trials; A. Sevinc: Member of Novartis Advisory Board; Institution participates in Novartis-sponsored clinical trials; Y. Shan: Member of Novartis Advisory Board; Institution participates in Novartis-sponsored clinical trials; Y. Shyr: Member of Novartis Advisory Board; Institution participates in Novartis-sponsored clinical trials.; V. Sriuranpong: Member of Novartis Advisory Board; Institution participates in Novartis-sponsored clinical trials; S.N. Turhal: Member of Novartis Advisory Board; Institution participates in Novartis-sponsored clinical trials; K. Yeh: Member of Novartis Advisory Board; Institution participates in Novartis-sponsored clinical trials; T. Hwang: Member of Novartis Advisory Board; Institution participates in Novartis-sponsored clinical trials.